These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 9629124)

  • 1. Tolcapone for Parkinson's disease.
    Med Lett Drugs Ther; 1998 Jun; 40(1028):60-1. PubMed ID: 9629124
    [No Abstract]   [Full Text] [Related]  

  • 2. Catechol-O-methyltransferase inhibitors: new options for Parkinson's disease.
    Leicht MJ; Mitchell SD
    S D J Med; 1999 Aug; 52(8):295-7. PubMed ID: 10453205
    [No Abstract]   [Full Text] [Related]  

  • 3. Catechol-O-methyltransferase inhibitors in Parkinson's disease.
    Henry C; Wilson JA
    Lancet; 1998 Jun; 351(9120):1965-6. PubMed ID: 9654299
    [No Abstract]   [Full Text] [Related]  

  • 4. Vitiligo associated with tolcapone and levodopa in a patient with Parkinson's disease.
    Sabaté M; Bosch A; Pedrós C; Figueras A
    Ann Pharmacother; 1999 Nov; 33(11):1228-9. PubMed ID: 10573327
    [No Abstract]   [Full Text] [Related]  

  • 5. [COMT inhibition with tolcapone].
    Nervenarzt; 1996 Jul; 67(7 Suppl Comt-hemmu):1-8. PubMed ID: 9404535
    [No Abstract]   [Full Text] [Related]  

  • 6. COMT inhibitors: management of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S45-51. PubMed ID: 12211139
    [No Abstract]   [Full Text] [Related]  

  • 7. Population pharmacokinetics of levodopa in patients with Parkinson's disease treated with tolcapone.
    Jorga K; Banken L; Fotteler B; Snell P; Steimer JL
    Clin Pharmacol Ther; 2000 Jun; 67(6):610-20. PubMed ID: 10872643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COMT inhibition and safety.
    Martignoni E; Blandini F; Pacchetti C; Nappi G
    Funct Neurol; 2001; 16(4 Suppl):135-40. PubMed ID: 11996508
    [No Abstract]   [Full Text] [Related]  

  • 9. [COMT inhibitors].
    Bornkessel B
    Med Monatsschr Pharm; 1999 May; 22(5):138-41. PubMed ID: 10365553
    [No Abstract]   [Full Text] [Related]  

  • 10. Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly.
    Jorga KM; Sedek G; Fotteler B; Zürcher G; Nielsen T; Aitken JW
    Clin Pharmacol Ther; 1997 Sep; 62(3):300-10. PubMed ID: 9333106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolcapone: COMT inhibition for the treatment of Parkinson's disease.
    Fahn S
    Neurology; 1998 May; 50(5 Suppl 5):S1-2. PubMed ID: 9591515
    [No Abstract]   [Full Text] [Related]  

  • 12. Tolcapone, a selective catechol-O-methyltransferase inhibitor for treatment of Parkinson's disease.
    Guay DR
    Pharmacotherapy; 1999 Jan; 19(1):6-20. PubMed ID: 9917075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First COMT inhibitor approved for Parkinson's disease.
    Am J Health Syst Pharm; 1998 Mar; 55(6):524, 526. PubMed ID: 9544322
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's disease.
    Chong DJ; Suchowersky O; Szumlanski C; Weinshilboum RM; Brant R; Campbell NR
    Clin Neuropharmacol; 2000; 23(3):143-8. PubMed ID: 10895397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolcapone: a review of its use in the management of Parkinson's disease.
    Keating GM; Lyseng-Williamson KA
    CNS Drugs; 2005; 19(2):165-84. PubMed ID: 15697329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COMT inhibition in Parkinson's disease: rationale and clinical relevance.
    Deleu D
    Acta Neurol Belg; 2000 Mar; 100(1):5-7. PubMed ID: 10779856
    [No Abstract]   [Full Text] [Related]  

  • 18. New options for treatment of Parkinson's disease.
    LeWitt PA
    Baillieres Clin Neurol; 1997 Apr; 6(1):109-23. PubMed ID: 9426871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment in Parkinson disease].
    Takáts A
    Orv Hetil; 2004 Apr; 145(15):833-4. PubMed ID: 15188639
    [No Abstract]   [Full Text] [Related]  

  • 20. Hepatotoxic profile of catechol-O-methyltransferase inhibitors in Parkinson's disease.
    Benabou R; Waters C
    Expert Opin Drug Saf; 2003 May; 2(3):263-7. PubMed ID: 12904105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.